Compare NetEase Inc (NTES) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs TransMedics Group Inc — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: NetEase Inc is far larger — about 27.8× TransMedics Group Inc's market cap, and NetEase Inc pays a 2.45% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and TransMedics Group Inc for 24 Days on average.
| NTES | TMDX | |
|---|---|---|
Market Cap | $76.09B | $2.74B |
Volume | 486,447 | 949,331 |
Sector | Technology | Health |
52-Week High | $152.85 | $150.42 |
52-Week Low | $109.26 | $61.99 |
Typical Hold Time | 73 Days | 24 Days |
Enterprise Value | $51.81B | $3.13B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.60, down 0.84% with neutral technical signals. The company maintains strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show mixed results with two misses and one beat. Analyst consensus remains strongly bullish with 82% buy ratings and $168 price target, representing 40% upside potential from current levels.
NTES presents compelling value with reasonable P/E of 15.9 and strong cash flow generation, but faces execution risks from inconsistent earnings performance and competitive pressures in gaming. The stock's current valuation discount to analyst targets offers opportunity, though investors should monitor Q3 2026 results for sustained growth trajectory.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
